Abstract:BackgroundHelicobacter pylori infection and its associated diseases represent a significant global health concern. Patients who cannot use amoxicillin pose a therapeutic challenge and necessitate alternative medications. Preliminary research indicates that cefuroxime demonstrates promising potential for eradicating H. pylori infection, and there is a lack of comprehensive review articles on the use of cefuroxime. Materials and MethodsThis study conducts a thorough systematic literature review and synthesis. A comprehensive systematic search was conducted in PubMed, Web of Science, EMBASE, China National Knowledge Infrastructure, China Biology Medicine disc, and Wanfang Data up to January 13, 2024. The search strategy utilized the following keywords: (Cefuroxime) AND (Helicobacter pylori OR Helicobacter nemestrinae OR Campylobacter pylori OR Campylobacter pylori subsp. pylori OR Campylobacter pyloridis OR H. pylori OR Hp) for both English and Chinese language publications. Sixteen studies from five different countries or regions were included in final literature review. ResultsAnalysis results indicate that H. pylori is sensitive to cefuroxime, with resistance rates similar to amoxicillin being relatively low. Regimens containing cefuroxime have shown favorable eradication rates, which were comparable to those of the regimens containing amoxicillin. Regarding safety, the incidence of adverse reactions in cefuroxime-containing eradication regimens was comparable to that of amoxicillin-containing regimens or other bismuth quadruple regimens, with no significant increase in allergic reactions in penicillin-allergic patients. Regarding compliance, studies consistently report high compliance rates for regimens containing cefuroxime. ConclusionCefuroxime can serve as an alternative to amoxicillin for the patients allergic to penicillin with satisfactory efficacies, safety, and compliance.

Resolution and Evaluation of 3-Chlorophenyl-3-hydroxypropionylhydroxamic Acid As Antivirulence Agent with Excellent Eradication Efficacy in Helicobacter Pylori Infected Mice.

Arylamino Containing Hydroxamic Acids As Potent Urease Inhibitors for the Treatment of Helicobacter Pylori Infection.

In vitro anti-Helicobacter pylori activity and antivirulence activity of cetylpyridinium chloride

Selective Killing of Helicobacter Pylori with Ph-Responsive Helix-Coil Conformation Transitionable Antimicrobial Polypeptides.

The Synthesis and Evaluation of Phenoxyacylhydroxamic Acids As Potential Agents for Helicobacter Pylori Infections

Antibacterial Activities of Peptide HF-18 Against Helicobacter pylori and its Virulence Protein CagA

Discovery of Cinnamic Acid Derivatives as Potent Anti-H. pylori Agents

Application of cefuroxime in the eradication therapy of <i>Helicobacter pylori</i> infection: A review article

Synthesis, Molecular Docking and Kinetic Properties of Β-Hydroxy-β-phenylpropionyl-hydroxamic Acids As Helicobacter Pylori Urease Inhibitors

A Bioresponsive Genetically Encoded Antimicrobial Crystal for the Oral Treatment of Helicobacter Pylori Infection

Effective Treatment of Helicobacter pylori Infection Using Supramolecular Antimicrobial Peptide Hydrogels

New indications for FDA-approved drugs: selective inhibition of growth of Helicobacter pylori by covalent allosteric regulation of urease

Multi-functional vesicles improve Helicobacter pylori eradication by a comprehensive strategy based on complex pathological microenvironment

Anti-Helicobacter Pylori Effectiveness and Targeted Delivery Performance of Amoxicillin-Uccs-2/tpp Nanoparticles Based on Ureido-Modified Chitosan Derivative

Azobenzenesulfonamide Carbonic Anhydrase Inhibitors as New Weapons to Fight Helicobacter pylori: Synthesis, Bioactivity Evaluation, In Vivo Toxicity, and Computational Studies

Dihydrotanshinone I Is Effective against Drug-Resistant Helicobacter pylori In Vitro and In Vivo

Construction and Optimization of Ph-Sensitive Nanoparticle Delivery System Containing PLGA and UCCs-2 for Targeted Treatment of Helicobacter Pylori.

3-Arylpropionylhydroxamic Acid Derivatives As Helicobacter Pylori Urease Inhibitors: Synthesis, Molecular Docking and Biological Evaluation

The Synthesis, Structure and Activity Evaluation of Pyrogallol and Catechol Derivatives As Helicobacter Pylori Urease Inhibitors

High-throughput Tandem-Microwell Assay for Ammonia Repositions FDA-Approved Drugs to Inhibit Helicobacter Pylori Urease

Design, Synthesis, and Efficacy Testing of Nitroethylene- and 7-Nitrobenzoxadiazol-Based Flavodoxin Inhibitors against Helicobacter pylori Drug-Resistant Clinical Strains and in Helicobacter pylori-Infected Mice